Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020
Journal of the American Heart Association · 2023
DOI: 10.1161/jaha.122.028869 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Mohammed Essa und 5 weiteren Autor:innen. Beteiligte Einrichtung: New England Heart and Vascular Institute Catholic Medical Center Manchester NH USA. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
2Y12 inhibitors (P2Y12is) are antiplatelet agents used in management of patients with atherosclerosis. 1,2The P2Y12is prasugrel and ticagrelor have more potent antiplatelet effects than clopidogrel and lead to lower rates of major adverse cardiovascular events and are therefore generally recommended over clopidogrel in patients with acute coronary syndrome. 1n a recent randomized clinical trial, prasugrel also decreased major adverse outcomes compared with ticagrelor with no difference in bleeding. 3Ticagrelor remains available only as a brand-name medication, whereas clopidogrel became generic in 2012 and prasugrel became generic in 2017.Generic medications can result in substantial cost reductions for patients and payers, although the impact of generic P2Y12i availability on total health care spending is unknown.In this study we examined recent trends in spending for P2Y12i among Medicare and Medicaid beneficiaries.We used the 2015 to 2020 Centers for Medicare and Medicaid Services Medicare Part D and Medicaid prescription drug spending data sets; all data are publicly available online. 4 Institutional review board approval was not required because the data did not include patient information.Total claims, total spending, and average spending per claim were determined in millions (M) of 2020 US dollars after adjusting for inflation
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- New England Heart and Vascular Institute Catholic Medical Center Manchester NH USA.
- Center for Outcomes Research and Evaluation, Yale New Haven Health System New Haven CT USA.
- Section of General Internal Medicine, Department of Medicine, Yale School of Medicine New Haven CT USA.
- Department of Health Policy and Management, Yale School of Public Health New Haven CT USA.
- Section of Cardiology, Department of Medicine University of California at San Francisco School of Medicine San Francisco CA USA.
- Section of Cardiovascular Medicine, Department of Medicine Yale School of Medicine; Center for Outcomes Research and Evaluation, Yale New Haven Health System New Haven CT USA.
ORCID-Profile: Mohammed Essa, Joseph S Ross, Sanket S Dhruva, Nihar R Desai, Robert W Yeh, Kamil F Faridi
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Essa, M., Ross, J. S., Dhruva, S. S., Desai, N. R., Yeh, R. W., & Faridi, K. F. (2023). Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.028869
Vancouver
Essa M, Ross JS, Dhruva SS, Desai NR, Yeh RW, Faridi KF. Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.028869
BibTeX
@article{Essa2023,
author = {Essa, Mohammed and Ross, Joseph S and Dhruva, Sanket S and Desai, Nihar R and Yeh, Robert W and Faridi, Kamil F},
title = {Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020},
journal = {Journal of the American Heart Association},
year = {2023},
doi = {10.1161/jaha.122.028869}
}
EUVIMED